U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Age-related macular degeneration: diagnosis and management. London: National Institute for Health and Care Excellence (NICE); 2018 Jan. (NICE Guideline, No. 82.)

Cover of Age-related macular degeneration

Age-related macular degeneration: diagnosis and management.

Show details

Appendix IReferences for included and cited studies

  1. Anon (2001) The Age-Related Eye Disease Study system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the Age-Related Eye Disease Study Report Number 6 American Journal of Ophthalmology 132 (5) 668–681 [PubMed: 11704028]
  2. Age-Related Eye Disease Study Research Group (2001) A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8 Archives of Ophthalmology 119 (10) 1417 [PMC free article: PMC1462955] [PubMed: 11594942]
  3. Ahmadieh H, Taei R, Riazi-Esfahani M et al. (2011) Intravitreal bevacizumab versus combined intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration: six-month results of a randomized clinical trial Retina 31 1819–1826 [PubMed: 21555967]
  4. Ajani UA, Christen WG, Manson JE et al. (1999) A prospective study of alcohol consumption and the risk of age-related macular degeneration Ann Epidemiol 172–177 [PubMed: 10192649]
  5. Almony A, Mansouri A, Shah GK et al. (2011) Efficacy of intravitreal bevacizumab after unresponsive treatment with intravitreal ranibizumab Can J Ophthalmol 46 182–185 [PubMed: 21708088]
  6. Amoaku WM, Chakravarthy U, Gale R et al. (2015) Defining response to anti-VEGF therapies in neovascular AMD Eye 29 (6) 721–731 [PMC free article: PMC4469673] [PubMed: 25882328]
  7. Arias L, Armada F, Donate J et al. (2009) Delay in treating age-related macular degeneration in Spain is associated with progressive vision loss Eye 23 (2) 326–333 [PubMed: 18202712]
  8. Athanasakis K, Fragoulakis V, Tsiantou V et al. (2012) Cost-effectiveness analysis of ranibizumab versus verteporfin photodynamic therapy, pegaptanib sodium, and best supportive care for the treatment of age-related macular degeneration in Greece Clinical therapeutics 34 (2) 446–456 [PubMed: 22289279]
  9. Azzolini C, Torreggiani A, Eandi C et al. (2013) A teleconsultation network improves the efficacy of anti-VEGF therapy in retinal diseases Journal of Telemedicine & Telecare 19 (8) 437–442 [PubMed: 24162839]
  10. Bakall B, Folk JC, Boldt HC, Sohn EH, Stone EM, Russell SR et al. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol 2013; 156(1):15–22 [PubMed: 23706500]
  11. Barikian A, Mahfoud Z, Abdulaal M et al. (2015) Induction with intravitreal bevacizumab every two weeks in the management of neovascular age-related macular degeneration American Journal of Ophthalmology 159 (1) 131–137 [PubMed: 25308787]
  12. Bartlett HE, Eperjesi F (2007) Effect of lutein and antioxidant dietary supplementation on contrast sensitivity in age-related macular disease: a randomized controlled trial European journal of clinical nutrition 61 (9) 1121–1127 [PubMed: 17268417]
  13. Bashshur ZF, Schakal AR, El-Mollayess GM et al. (2011) Ranibizumab monotherapy versus single-session verteporfin photodynamic therapy combined with as-needed ranibizumab treatment for the management of neovascular age-related macular degeneration Retina (Philadelphia, Pa.) 31 636–644 [PubMed: 21124254]
  14. Batioglu F, Demirel S, Ozmert E et al. (2015) Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD BMC ophthalmol 15 40- [PMC free article: PMC4407797] [PubMed: 25885684]
  15. Beatty S, Chakravarthy U, Nolan JM et al. (2013) Secondary outcomes in a clinical trial of carotenoids with coantioxidants versus placebo in early age-related macular degeneration Ophthalmology 120 (3) 600–606 [PubMed: 23218821]
  16. Berg K, Pedersen TR, Sandvik L et al. (2015) Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol Ophthalmology 122 (1) 146–152 [PubMed: 25227499]
  17. Berrow EJ, Bartlett HE, Eperjesi F et al. (2013) The effects of a lutein-based supplement on objective and subjective measures of retinal and visual function in eyes with age-related maculopathy–a randomised controlled trial British journal of nutrition 109(11) 2008–2014 [PubMed: 23084077]
  18. Birk T, Hickl S, Wahl HW et al. (2004) Development and pilot evaluation of a psychosocial intervention program for patients with age-related macular degeneration The Gerontologist 44 (6) 836–843 [PubMed: 15611220]
  19. Biswas P, Sengupta S, Choudhary R et al. (2011) Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration Indian journal of ophthalmology 59 (3) 191- [PMC free article: PMC3120237] [PubMed: 21586838]
  20. Bittner AK, Torr-Brown S, Arnold E et al. (2014) Improved Adherence to Vision Self-monitoring with the Vision and Memory Stimulating (VMS) Journal for Non-neovascular Age-related Macular Degeneration during a Randomized Controlled Trial Journal of clinical & experimental ophthalmology 5 (1) 320- [PMC free article: PMC4004088] [PubMed: 24791222]
  21. Boekhoorn SS, Vingerling JR, Hofman A et al. (2008) Alcohol consumption and risk of aging macula disorder in a general population: the Rotterdam Study Archives of ophthalmology (Chicago, Ill.: 1960) 834–839 [PubMed: 18541849]
  22. Boulanger-Scemama E, Querques G, About F et al. (2015) Ranibizumab for exudative age-related macular degeneration: A five year study of adherence to follow-up in a real-life setting Journal Francais d Opthalmologie 38 620–627 [PubMed: 25913443]
  23. Brader HS, Ying GS, Martin ER et al. (2011) New grading criteria allow for earlier detection of geographic atrophy in clinical trials Investigative ophthalmology & visual science 52 (12) 9218–9225 [PMC free article: PMC3302429] [PubMed: 22039251]
  24. Bressler SB, Maguire MG, Bressler NM et al. (1990) Relationship of drusen and abnormalities of the retinal pigment epithelium to the prognosis of neovascular macular degeneration. The Macular Photocoagulation Study Group Archives of ophthalmology (Chicago, Ill.: 1960) 1442–1447 [PubMed: 1699513]
  25. Bressler SB, Vitale S, Hawkins BS, et al. (1995) Laser to drusen trial-an assessment of short-term safety within a randomized, prospective controlled clinical-triallippincott-raven publ 227 east washington square, philadelphia, PA 19106, p S255–S255.
  26. Brody BL, Roch-Levecq AC, Gamst AC et al. (2002) Self-management of age-related macular degeneration and quality of life: a randomized controlled trial Archives of Ophthalmology 120 (11) 1477–1483 [PubMed: 12427060]
  27. Brody BL, Roch-Levecq AC, Thomas RG et al. (2005) Self-management of age-related macular degeneration at the 6-month follow-up: a randomized controlled trial Archives of Ophthalmology 123 (1) 46–53 [PubMed: 15642811]
  28. Brody BL, Roch-Levecq A-C, Kaplan RM et al. (2006) Age–Related Macular Degeneration: Self–Management and Reduction of Depressive Symptoms in a Randmized, Contolled Study Journal of the American Geriatrics society 54 (10) 1557–1562 [PubMed: 17038074]
  29. Brown DM, Kaiser PK, Michels M et al. (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration New England Journal of Medicine 355 (14) 1432–1444 [PubMed: 17021319]
  30. Brown DM, Michels M, Kaiser PK et al. (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study Ophthalmology 116 (1) 57–65 [PubMed: 19118696]
  31. Brown GC, Sharma S, Brown MM et al. (2000) Utility values and age-related macular degeneration Archives of Ophthalmology 118 (1) 47–51 [PubMed: 10636413]
  32. Brown GC, Brown MM, Brown HC et al. (2007) A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration Ophthalmology 114 (6) 1170–1178 [PubMed: 17320964]
  33. Brown MM, Brown GC, Sharma S et al. (2003) Quality of life associated with visual loss: a time tradeoff utility analysis comparison with medical health states Ophthalmology 110 (6) 1076–1081 [PubMed: 12799229]
  34. Buckle M, Donachie PH, Johnston RL (2016) Long-term outcomes of intravitreal ranibizumab for neovascular age-related macular degeneration in a well defined region of the UK British Journal of Ophthalmology 100 (2) 240–245 [PubMed: 26124462]
  35. Bunce C, Xing W, Wormald R (2010) Causes of blind and partial sight certifications in England and Wales: April 2007-March 2008 Eye 24 (11) 1692–1699 [PubMed: 20847749]
  36. Burton AE, Shaw RL, Gibson JM (2013) ‘I’d like to know what causes it, you know, anything I’ve done?’ Are we meeting the information and support needs of patients with macular degeneration? A qualitative study BMJ Open 3 (11) e003306 [PMC free article: PMC3822314] [PubMed: 24202055]
  37. Burton AE, Shaw R, Gibson J (2013) Experiences of patients with age-related macular degeneration receiving anti-vascular endothelial growth factor therapy: A qualitative study British Journal of Visual Impairment 31 178–188
  38. Busbee BG, Ho AC, Brown DM et al. (2013) Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration Ophthalmology 120 (5) 1046–1056 [PubMed: 23352196]
  39. Busija L, Pausenberger E, Haines TP et al. (2011) Adult measures of general health and health-related quality of life: Medical Outcomes Study Short Form 36 Item (SF 36) and Short Form 12 Item (SF12) Health Surveys, Nottingham Health Profile (NHP), Sickness Impact Profile (SIP), Medical Outcomes Study Short Form 6D (SF 6D), Health Utilities Index Mark 3 (HUI3), Qualityu of Well–Being Scale (QWB), and Assessment of Quality of Life (AQOL) Arthritis care & research 63 (S11) S383–S412 [PubMed: 22588759]
  40. Butt T, Crossland MD, West P et al. (2015) Simulation contact lenses for AMD health state utility values in NICE appraisals: a different reality British Journal of Ophthalmology 99 (4) 540–544 [PMC free article: PMC4392203] [PubMed: 25351679]
  41. Butt T, Lee A, Lee C et al. (2015) The cost-effectiveness of initiating ranibizumab therapy in eyes with neovascular AMD with good vision: an economic model using real-world outcomes BMJ Open 5 (5) e006535- [PMC free article: PMC4431059] [PubMed: 25943370]
  42. Cachulo L, Silva R, Fonseca P et al. (2010) Early markers of choroidal neovascularization in the fellow eye of patients with unilateral exudative age-related macular degeneration Ophthalmologica 225 (3) 144–149 [PubMed: 21071996]
  43. CATT Research Group (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 2011 (364) 1897–1908 [PMC free article: PMC3157322] [PubMed: 21526923]
  44. Chakravarthy U, Wong TY, Fletcher A et al. (2010) Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis BMC ophthalmology 10 (1) 31- [PMC free article: PMC3009619] [PubMed: 21144031]
  45. Chakravarthy U, Harding SP, Rogers CA et al. (2012) Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial Ophthalmology 119 (7) 1399–1411 [PubMed: 22578446]
  46. Chakravarthy U, Harding SP, Rogers CA et al. (2013) Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial The Lancet 382 (9900) 1258–1267 [PubMed: 23870813]
  47. Chakravarthy U, Harding SP, Rogers CA et al. (2015) A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN) [PMC free article: PMC4781416] [PubMed: 26445075]
  48. Chan C, Abraham P, Sarraf D et al. (2015) Earlier therapeutic effects associated with high dose (2.0 mg) Ranibizumab for treatment of vascularized pigment epithelial detachments in age-related macular degeneration Eye (London, England) 29 (1) 80–87 [PMC free article: PMC4289828] [PubMed: 25277305]
  49. Chan CK, Jain A, Sadda S, Varshney N. Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2014; 112:160–198 [PMC free article: PMC4307397] [PubMed: 25646034]
  50. Chang AA, Li H, Broadhead GK et al. (2013) Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration 41 52- [PubMed: 24144450]
  51. Chang AA, Li H, Broadhead GK et al. (2014) Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration Ophthalmology 121 188–192 [PubMed: 24144450]
  52. Chasan JE, Delaune B, Maa AY et al. (2014) Effect of a teleretinal screening program on eye care use and resources JAMA Ophthalmology 132 (9) 1045–1051 [PubMed: 24875731]
  53. Cheong AM, Lovie-Kitchin JE, Bowers AR et al. (2005) Short-term in-office practice improves reading performance with stand magnifiers for people with AMD Optometry and vision science 82 (2) 114–127 [PubMed: 15711458]
  54. Cheung CMG, Yanagi Y, Mohla A et al. (2016) Characterization and differentiation of polypoidal choroidal vasculopathy using swept source optical coherence tomography angiography Retina no- [PubMed: 27828911]
  55. Cheung CMG, Laude A, Wong W et al. (2015) Improved specificity of polypoidal choroidal vasculopathy diagnosis using a modified Everest criteria Retina 35 (7) 1375–1380 [PubMed: 26102436]
  56. Chew EY, Sperduto RD, Milton RC et al. (2009) Risk of advanced age-related macular degeneration after cataract surgery in the Age-Related Eye Disease Study: AREDS report 25 Ophthalmology 297–303 [PMC free article: PMC3021282] [PubMed: 19091420]
  57. Chew EY, Clemons TE, SanGiovanni JP et al. (2013) Age-Related Eye Disease Study 2 Research Group. Lutein+ zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial JAMA 309 (19) 2005–2015 [PubMed: 23644932]
  58. Chew EY, Clemons TE, Bressler SB et al. (2014) Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study Ophthalmology 121 535–544 [PMC free article: PMC3918479] [PubMed: 24211172]
  59. Chew EY, Clemons TE, SanGiovanni JP et al. (2014) Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3 JAMA Ophthalmology 132 (2) 142–149 [PMC free article: PMC4636082] [PubMed: 24310343]
  60. Chiu CJ, Milton RC, Klein R et al. (2007) Dietary carbohydrate and the progression of age-related macular degeneration: A prospective study from the Age-Related Eye Disease Study Am.J.Clin.Nutr. 1210–1218 [PubMed: 17921404]
  61. Chiu CJ, Klein R, Milton RC et al. (2009) Does eating particular diets alter the risk of age-related macular degeneration in users of the Age-Related Eye Disease Study supplements? Br.J.Ophthalmol. 1241–1246 [PMC free article: PMC3033729] [PubMed: 19508997]
  62. Cho H, Shah CP, Weber M et al. (2013) Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab Br J Ophthalmol 97 1032–1035 [PubMed: 23766432]
  63. Choroidal Neovascularization Prevention Trial Research Group (1998) Choroidal neovascularization in the choroidal neovascularization prevention trial Ophthalmology 105 (8) 1364–1372 [PubMed: 9709744]
  64. Christ SL, Lee DJ, Lam BL et al. (2008) Assessment of the effect of visual impairment on mortality through multiple health pathways: structural equation modeling Investigative ophthalmology & visual science 49 (8) 3318–3323 [PubMed: 18362104]
  65. Christen WG, Glynn RJ, Ajani UA et al. (2001) Age-related maculopathy in a randomized trial of low-dose aspirin among US physicians Archives of ophthalmology (Chicago, Ill.: 1960) 1143–1149 [PubMed: 11483080]
  66. Christen WG, Glynn RJ, Chew EY et al. (2009) Low-dose aspirin and medical record-confirmed age-related macular degeneration in a randomized trial of women Ophthalmology 2386–2392 [PMC free article: PMC2787838] [PubMed: 19815293]
  67. Claxton L, Hodgson R, Taylor M et al. (2016) Simulation Modelling in Ophthalmology: Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related Macular Degeneration in the United Kingdom PharmacoEconomics 1–12 [PubMed: 27787744]
  68. Cohen SY, Creuzot-Garcher C, Darmon J et al. (2007) Types of choroidal neovascularisation in newly diagnosed exudative age-related macular degeneration The British journal of ophthalmology 91 (9) 1173–1176 [PMC free article: PMC1954889] [PubMed: 17383997]
  69. Colquitt JL, Jones J, Tan SC et al. (2008) Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation Health Technology Assessment 12 (16) 1–222 [PubMed: 18462575]
  70. Complications of Age-Related Macular Degeneration Prevention Trial, 20080911 (2008) Risk factors for choroidal neovascularization and geographic atrophy in the complications of age-related macular degeneration prevention trial Ophthalmology 1474–1479 [PubMed: 18502512]
  71. Complications of Age-Related Macular Degeneration Prevention Trial Research Group (2006) Laser treatment in patients with bilateral large drusen: the complications of age-related macular degeneration prevention trial Ophthalmology 113 (11) 1974–1986 [PubMed: 17074563]
  72. Coscas G, Yamashiro K, Coscas F et al. (2014) Comparison of exudative age-related macular degeneration subtypes in Japanese and French Patients: multicenter diagnosis with multimodal imaging American Journal of Ophthalmology 158 (2) 309–318 [PubMed: 24844973]
  73. Coscas GJ, Lupidi M, Coscas F et al. (2015) Optical coherence tomography angiography versus traditional multimodal imaging in assessing the activity of exudative age-related macular degeneration: A New Diagnostic Challenge Retina 35 (11) 2219–2228 [PubMed: 26398697]
  74. Crossland MD, Helman CG, Feely MP et al. (2007) Why did i lose vision? A qualitative study of patient perceptions of the causes of age-related macular disease Visual Impairment Research 9 (1) 39–43
  75. Curtis, L. and Burns, A. (2016) Unit costs of health and social care 2016. Personal Social Services Research Unit, University of Kent.:
  76. Czoski Murray C, Carlton J, Brazier J et al. (2009) Valuing Condition–Specific Health States Using Simulation Contact Lenses Value in Health 12 (5) 793–799 [PubMed: 19490557]
  77. Dahlin I, S, Sjostrand J et al. (1996) Planning a health education programme for the elderly visually impaired person - A focus group study Disability and Rehabilitation 18 (10) 515–522 [PubMed: 8902424]
  78. Dakin HA, Wordsworth S, Rogers CA et al. (2014) Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial BMJ Open 4 (7) e005094- [PMC free article: PMC4120317] [PubMed: 25079928]
  79. Danis RP, Domalpally A, Chew EY et al. (2013) Methods and reproducibility of grading optimized digital color fundus photographs in the Age-Related Eye Disease Study 2 (AREDS2 Report Number 2) Investigative ophthalmology & visual science 54 (7) 4548–4554 [PMC free article: PMC3706107] [PubMed: 23620429]
  80. Datseris I, Kontadakis GA, Diamanti R et al. (2015) Prospective comparison of low-fluence photodynamic therapy combined with intravitreal bevacizumab versus bevacizumab monotherapy for choroidal neovascularization in age-related macular degeneration Seminars in Ophthalmology 30 112–117 [PubMed: 24117412]
  81. Davis MD, Gangnon RE, Lee LY et al. (2005) The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS Report No. 17 Archives of ophthalmology (Chicago, Ill.: 1960) 123 (11) 1484–1498 [PMC free article: PMC1472813] [PubMed: 16286610]
  82. Davis S, Stevenson M, Tappenden P et al. (2014) NICE DSU Technical Support Document 15: Cost-Effectiveness Modelling Using Patient-Level Simulation School of Health and Related Research, University of Sheffield [PubMed: 27466644]
  83. de Carlo T, Bonini Filho MA, Chin AT et al. (2015) Spectral Domain Optical Coherence Tomography Angiography (OCTA) of Choroidal Neovascularization Investigative ophthalmology & visual science 56 (7) 3962–3962
  84. De Salvo G, Vaz-Pereira S, Keane PA et al. (2014) Sensitivity and specificity of spectral-domain optical coherence tomography in detecting idiopathic polypoidal choroidal vasculopathy American Journal of Ophthalmology 158 (6) 1228–1238 [PubMed: 25152500]
  85. Department of Health (2015) NHS reference costs 2014 to 2015
  86. Department of Health (2016) Drugs and pharmaceutical electronic market information (eMit)
  87. Do DV, Gower EW, Cassard SD et al. (2012) Detection of new-onset choroidal neovascularization using optical coherence tomography: the AMD DOC Study Ophthalmology 119 (4) 771–778 [PubMed: 22297028]
  88. Dobbelsteyn D, McKee K, Bearnes RD et al. (2015) What percentage of patients presenting for routine eye examinations require referral for secondary care? A study of referrals from optometrists to ophthalmologists Clinical & Experimental Optometry 98 (3) 214–217 [PubMed: 25756613]
  89. Droege KM, Muether PS, Hermann MM et al. (2013) Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life Graefes Archive for Clinical & Experimental Ophthalmology 251 1281–1284 [PubMed: 23086225]
  90. Eadie JA, Gottlieb JL, Ip MS et al. (2014) Response to aflibercept in patients with persistent exudation despite prior treatment with bevacizumab or ranibizumab for age-related macular degeneration Ophthalmic Surg Lasers Imaging Retina 45 394–397 [PubMed: 25230402]
  91. Ehlken C, Jungmann S, Bohringer D et al. (2014) Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD Eye 28 538–545 [PMC free article: PMC4017123] [PubMed: 24722504]
  92. Eklund K, Sonn U, Dahlin-Ivanoff S (2004) Long-term evaluation of a health education programme for elderly persons with visual impairment. A randomized study Disability & Rehabilitation 26 (7) 401–409 [PubMed: 15204476]
  93. Eklund K, Sjostrand J, Dahlin-Ivanoff S (2008) A randomized controlled trial of a health-promotion programme and its effect on ADL dependence and self-reported health problems for the elderly visually impaired Scandinavian Journal of Occupational Therapy 15 (2) 68–74 [PubMed: 17852958]
  94. El-Mollayess GM, Mahfoud Z, Schakal AR et al. (2013) Intravitreal bevacizumab in the management of neovascular age-related macular degeneration: effect of baseline visual acuity Retina 33 (9) 1828–1835 [PubMed: 23615342]
  95. El-Mollayess GM, Mahfoud Z, Schakal AR et al. (2012) Fixed-interval versus OCT-guided variable dosing of intravitreal bevacizumab in the management of neovascular age-related macular degeneration: a 12-month randomized prospective study American Journal of Ophthalmology 153 (3) 481–489 [PubMed: 22014603]
  96. Eldem BM, Muftuoglu G, Topbas S et al. (2015) A randomized trial to compare the safety and efficacy of two ranibizumab dosing regimens in a Turkish cohort of patients with choroidal neovascularization secondary to AMD Acta Opthalmologica 93 (6) e458–e464 [PubMed: 25160859]
  97. Elliot DB, Yang KC, Whitaker D (1995) Visual acuity changes throughout adulthood in normal, healthy eyes: seeing beyond 6/6 Optometry & Vision Science 72 (3) 186–191 [PubMed: 7609941]
  98. Elshout M, van der Reis MI, Webers CA et al. (2012) A new epidemiological aid in deciding whether to continue or stop a treatment Invest Ophthalmol Vis Sci 53 4331–4336 [PubMed: 22661474]
  99. Elshout M, van der Reis MI, Webers CA et al. (2014) The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters Graefe’s archive for clinical and experimental ophthalmology 252 (12) 1911–1920 [PubMed: 24777708]
  100. Engman SJ, Edwards AO, Bakri SJ (2011) Administration of repeat intravitreal anti-VEGF drugs by retina specialists in an injection-only clinic for patients with exudative AMD: patient acceptance and safety Seminars in Ophthalmology 26 (6) 380–386 [PubMed: 22044336]
  101. Eter N, Spaide RF (2005) Comparison of fluorescein angiography and optical coherence tomography for patients with choroidal neovascularization after photodynamic therapy Retina 25 (6) 691–696 [PubMed: 16141855]
  102. Evans JR, Lawrenson JG (2012) Antioxidant vitamin and mineral supplements for slowing the progression of age–related macular degeneration The Cochrane Library [PubMed: 23152201]
  103. Fang K, Tian J, Qing X et al. (2013) Predictors of visual response to intravitreal bevacizumab for treatment of neovascular age-related macular degeneration Journal of ophthalmology 2013 676049- [PMC free article: PMC3771417] [PubMed: 24069533]
  104. Fassnacht-Riederle H, Becker M, Graf N et al. (2014) Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD Graefes Arch Clin Exp Ophthalmol 252 1705–1709 [PMC free article: PMC4218980] [PubMed: 24614949]
  105. Figueroa MS, Regueras A, Bertrand J (1994) Laser photocoagulation to treat macular soft drusen in age-related macular degeneration Retina 14 (5) 391–396 [PubMed: 7899712]
  106. Finger RP, Wu Z, Luu CD et al. (2014) Reticular pseudodrusen: a risk factor for geographic atrophy in fellow eyes of individuals with unilateral choroidal neovascularization Ophthalmology 1252–1256 [PMC free article: PMC4047161] [PubMed: 24518615]
  107. Fleiss JL (1971) Measuring nominal scale agreement among many raters Psychological bulletin 76 (5) 378-
  108. Fletcher EC, Lade RJ, Adewoyin T et al. (2008) Computerized model of cost-utility analysis for treatment of age-related macular degeneration Ophthalmology 115 (12) 2192–2198 [PubMed: 18930556]
  109. Frennesson CI, Bek T, Jaakkola A et al. (2009) Prophylactic laser treatment of soft drusen maculopathy: a prospective, randomized Nordic study Acta ophthalmologica 87 (7) 720–724 [PubMed: 18937820]
  110. Frennesson IC, Nilsson SE (1995) Effects of argon (green) laser treatment of soft drusen in early age-related maculopathy: a 6 month prospective study British Journal of Ophthalmology 79 (10) 905–909 [PMC free article: PMC505291] [PubMed: 7488578]
  111. Friberg TR, Musch DC, Lim JI et al. (2006) Prophylactic treatment of age-related macular degeneration report number 1: 810-nanometer laser to eyes with drusen. Unilaterally eligible patients Ophthalmology 113 (4) 612–622 [PubMed: 16581422]
  112. Friberg TR, Brennen PM, Freeman WR (2009) Prophylactic treatment of age-related macular degeneration report number 2: 810-nanometer laser to eyes with drusen: bilaterally eligible patients Ophthalmic Surgery, Lasers & Imaging Retina 40 (6) 530- [PubMed: 19928717]
  113. Friedman SM, Margo CE (2000) Choroidal neovascular membranes: reproducibility of angiographic interpretation American Journal of Ophthalmology 130 (6) 839–841 [PubMed: 11124312]
  114. Frisen L, Frisen M (1981) How good is normal visual acuity? Graefe’s archive for clinical and experimental ophthalmology 215 (3) 149–157 [PubMed: 6908464]
  115. Gehlbach P, Li T, Hatef E (2015) Statins for age–ÇÉrelated macular degeneration The Cochrane Library [PMC free article: PMC4736139] [PubMed: 25675254]
  116. Gerding H (2015) Functional and anatomic efficacy of a conversion to aflibercept in eyes with age-related macular degeneration after long-term ranibizumab treatment Klinische Monatsblatter fur Augenheilkunde 232 (4) 560–563 [PubMed: 25902122]
  117. Gharbiya M, Iannetti L, Parisi F et al. (2014) Visual and anatomical outcomes of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration Biomed Res Int 2014 273754- [PMC free article: PMC4033502] [PubMed: 24895562]
  118. Ghazala F, Hovan M, Mahmood S (2013) Improving treatment provision of Wet AMD with intravitreal ranibizumab BMJ Quality Improvement Reports 2 (1) [PMC free article: PMC4652712] [PubMed: 26734182]
  119. Ghosh W, Wickstead R, Claxton L et al. (2016) The Cost-Effectiveness of Ranibizumab Treat and Extend Regimen Versus Aflibercept in the UK Advances in therapy 33 (9) 1660–1676 [PubMed: 27457470]
  120. Giani A, Luiselli C, Esmaili DD et al. (2011) Spectral-domain optical coherence tomography as an indicator of fluorescein angiography leakage from choroidal neovascularization Investigative ophthalmology & visual science 52 (8) 5579–5586 [PubMed: 21693602]
  121. Gillespie BW, Musch DC, Niziol LM et al. (2014) Estimating Minimally Important Differences for Two Vision-Specific Quality of Life Measures Minimally Important Difference for NEI-VFQ and VAQ Investigative ophthalmology & visual science 55 (7) 4206–4212 [PMC free article: PMC4095718] [PubMed: 24906863]
  122. Gillies MC, Campain A, Barthelmes D et al. (2015) Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration: Data from an Observational Study Ophthalmology 122 (9) 1837–1845 [PubMed: 26096346]
  123. Gokce G, Durukan AH, Koylu MT, Kucukevcilioglu M. Efficacy of aflibercept on exudative age-related macular degeneration in patients exhibiting complete ranibizumab resistance and tachyphylaxis. Arq Bras Oftalmol 2016; 79(6):384–389 [PubMed: 28076566]
  124. Gomi F, Oshima Y, Mori R et al. (2015) Initial Versus Delayed Photodynamic Therapy in Combination with Ranibizumab for Treatment of Polypoidal Choroidal Vasculopathy Retina (Philadelphia, Pa.) 35 1569–1576 [PubMed: 25830698]
  125. Gong J, Yu S, Gong Y et al. (2016) The Diagnostic Accuracy of Optical Coherence Tomography Angiography for Neovascular Age-Related Macular Degeneration: A Comparison with Fundus Fluorescein Angiography Journal of ophthalmology 2016 7521478- [PMC free article: PMC4821972] [PubMed: 27110394]
  126. Goudie C, Lunt D, Reid S et al. (2014) Ophthalmic digital image transfer: benefits to triage, patient care and resource Ophthalmic & Physiological Optics 34 (6) 628–635 [PubMed: 25223370]
  127. Grewal DS, Gill MK, Sarezky D, Lyon AT, Mirza RG. Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results. Eye (Lond) 2014; 28(7):895–899 [PMC free article: PMC4094798] [PubMed: 24833178]
  128. Grieve R, Guerriero C, Walker J et al. (2009) Verteporfin photodynamic therapy cohort study: Report 3: Cost effectiveness and lessons for future evaluations Ophthalmology 116 (12) 2471–2477 [PubMed: 19948278]
  129. Griffin DR, Richmond PP, Olson JC (2014) Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration J Ophthalmol 2014 497178- [PMC free article: PMC4258314] [PubMed: 25505976]
  130. Grunwald JE, Daniel E, Huang J et al. (2014) Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials Ophthalmology 150–161 [PMC free article: PMC3892560] [PubMed: 24084496]
  131. Guymer RH, Baird PN, Varsamidis M et al. (2013) Proof of concept, randomized, placebo-controlled study of the effect of simvastatin on the course of age-related macular degeneration PLoS One 8 (12) e83759- [PMC free article: PMC3877099] [PubMed: 24391822]
  132. Hageman GS, Gehrs K, Johnson LV et al. (2008) Age-related macular degeneration (AMD)
  133. Hahn P, Acquah K, Cousins SW et al. (2013) Ten-year incidence of age-related macular degeneration according to diabetic retinopathy classification among medicare beneficiaries Retina (Philadelphia, Pa.) 911–919 [PMC free article: PMC3634874] [PubMed: 23407352]
  134. Hall LB, Zebardast N, Huang JJ, Adelman RA. Aflibercept in the treatment of neovascular age-related macular degeneration in previously treated patients. J Ocul Pharmacol Ther 2014; 30(4):346–352 [PubMed: 24552305]
  135. Hamada S, Jain S, Sivagnanavel V et al. (2006) Drusen classification in bilateral drusen and fellow eye of exudative age-related macular degeneration Eye (London, England) 20 (2) 199–202 [PubMed: 15746948]
  136. Hariri A, Diniz B, Fou LV, Lam LA, Nittala MG, Sadda SR. Quantitative OCT subanalysis of eyes with choroidal neovascularization switched from multiple injections of bevacizumab or ranibizumab to intravitreal aflibercept. Ophthalmic Surg Lasers Imaging Retina 2015; 46(2):195–200 [PubMed: 25707044]
  137. Hatz K, Schneider U, Henrich PB et al. (2015) Ranibizumab plus verteporfin photodynamic therapy in neovascular age-related macular degeneration: 12 months of retreatment and vision outcomes from a randomized study Ophthalmologica 233 66–73 [PubMed: 25471330]
  138. Hatz K, Prunte C. Intravitreal aflibercept in neovascular age-related macular degeneration with limited response to ranibizumab: a treat-and-extend trial. Retina 2017; 37(6):1185–1192 [PubMed: 27652915]
  139. Heier JS, Boyer D, Nguyen QD et al. (2011) The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing Ophthalmology 118 (6) 1098–1106 [PubMed: 21640258]
  140. Heier JS, Brown DM, Chong V et al. (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration Ophthalmology 119 (12) 2537–2548 [PubMed: 23084240]
  141. Henschel A, Spital G, Lommatzsch A et al. (2009) Optical coherence tomography in neovascular age related macular degeneration compared to fluorescein angiography and visual acuity European Journal of Ophthalmology 19 (5) 831–835 [PubMed: 19787605]
  142. Hernandez-Pastor LJ, Ortega A, Garcia-Layana A et al. (2008) Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration Clinical therapeutics 30 (12) 2436–2451 [PubMed: 19167602]
  143. Hessellund A, Larsen DA, Bek T (2012) The predictive value of subjective symptoms and clinical signs for the presence of treatment–requiring exudative age–related macular degeneration Acta ophthalmologica 90 (5) 471–475 [PubMed: 21232080]
  144. Heussen FM, Shao Q, Ouyang Y et al. (2014) Clinical outcomes after switching treatment from intravitreal ranibizumab to aflibercept in neovascular age-related macular degeneration Graefes Arch Clin Exp Ophthalmol 252 909–915 [PubMed: 24362854]
  145. Higgins JP, Green S (2011) Cochrane handbook for systematic reviews of interventions. 4 edition. John Wiley & Sons.
  146. Hirneiss C (2014) The impact of a better-seeing eye and a worse-seeing eye on vision-related quality of life Clinical ophthalmology (Auckland, NZ) 8 1703- [PMC free article: PMC4159393] [PubMed: 25214763]
  147. Holz FG, Jorzik J, Schutt F et al. (2003) Agreement among ophthalmologists in evaluating fluorescein angiograms in patients with neovascular age-related macular degeneration for photodynamic therapy eligibility (FLAP-study) Ophthalmology 110 (2) 400–405 [PubMed: 12578787]
  148. Homer N, Grewal DS, Mirza RG et al. (2015) Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results Eye 29 1152–1155 [PMC free article: PMC4565952] [PubMed: 26021870]
  149. Hopley C, Salkeld G, Mitchell P (2004) Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration British Journal of Ophthalmology 88 (8) 982–987 [PMC free article: PMC1772258] [PubMed: 15258009]
  150. Howard KP, Klein Barbara EK, Lee KE et al. (2014) Measures of body shape and adiposity as related to incidence of age-related eye diseases: observations from the Beaver Dam Eye Study Invest Ophthalmol Vis Sci 2592–2598 [PMC free article: PMC3995678] [PubMed: 24667857]
  151. Huang YM, Dou HL, Huang FF et al. (2015) Changes following supplementation with lutein and zeaxanthin in retinal function in eyes with early age-related macular degeneration: a randomised, double-blind, placebo-controlled trial British Journal of Ophthalmology 99 (3) 371–375 [PubMed: 25228440]
  152. Hurley SF, Matthews JP, Guymer RH (2008) Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration Cost Effectiveness and Resource Allocation 6 (1) 1- [PMC free article: PMC2443361] [PubMed: 18573218]
  153. Jaeschke R, Guyatt GH, Sackett DL et al. (1994) Users’ Guides to the Medical Literature: III. How to Use an Article About a Diagnostic Test B. What Are the Results and Will They Help Me in Caring for My Patients? JAMA 271 (9) 703–707 [PubMed: 8309035]
  154. Joint Formulary Committee (2016) British National Formulary. BMJ Group and Pharmaceutical Press.
  155. Jorstad OK, Faber RT, Moe MC. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol. Acta Ophthalmol 2017 [PubMed: 28556485]
  156. Jung JJ, Chen CY, Mrejen S et al. (2014) The incidence of neovascular subtypes in newly diagnosed neovascular age-related macular degeneration American Journal of Ophthalmology 158 (4) 769–779 [PubMed: 25034111]
  157. Kaiser PK, Boyer DS, Cruess AF et al. (2012) Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study Ophthalmology 119 1001–1010 [PubMed: 22444829]
  158. Kaiser PK, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (2006) Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension Graefe’s archive for clinical and experimental ophthalmology 244 (9) 1132–1142 [PubMed: 16538452]
  159. Kaiser PK (2009) Verteporfin PDT for subfoveal occult CNV in AMD: two-year results of a randomized trial Current medical research and opinion 25 (8) 1853–1860 [PubMed: 19530976]
  160. Kaiser RS, Gupta OP, Regillo CD et al. (2012) Ranibizumab for eyes previously treated with pegaptanib or bevacizumab without clinical response Ophthalmic Surg Lasers Imaging 43 13–19 [PubMed: 21986085]
  161. Kaltenthaler E, Tappenden P, Paisley S et al. (2011) NICE DSU technical support document 13: identifying and reviewing evidence to inform the conceptualisation and population of cost-effectiveness models Sheffield: Decision Support Unit, ScHARR, University of Sheffield [PubMed: 28481494]
  162. Kamalarajah S, Silvestri G, Sharma N et al. (2004) Surveillance of endophthalmitis following cataract surgery in the UK Eye 18 (6) 580–587 [PubMed: 15184923]
  163. Kawashima Y, Oishi A, Tsujikawa A et al. (2015) Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy Graefes Arch Clin Exp Ophthalmol 253 1471–1477 [PubMed: 25391986]
  164. Khurana RN, Dupas B, Bressler NM (2010) Agreement of time-domain and spectral-domain optical coherence tomography with fluorescein leakage from choroidal neovascularization Ophthalmology 117 (7) 1376–1380 [PubMed: 20452027]
  165. Kind P, Hardman G, Macran S (1999) UK population norms for EQ-5D. 172 edition. Centre for Health Economics, University of York York.
  166. Klein Barbara EK, Howard KP, Gangnon RE et al. (2012) Long-term use of aspirin and age-related macular degeneration JAMA 2469–2478 [PMC free article: PMC3630794] [PubMed: 23288416]
  167. Klein ML, Francis PJ, Ferris FL, III et al. (2011) Risk assessment model for development of advanced age-related macular degeneration Archives of ophthalmology (Chicago, Ill.: 1960) 129 (12) 1543–1550 [PubMed: 21825180]
  168. Klein ML, Francis PJ, Ferris FL et al. (2011) Risk assessment model for development of advanced age-related macular degeneration Arch Ophthalmol 1543–1550 [PubMed: 21825180]
  169. Klein R, Klein BE, Knudtson MD et al. (2007) Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study Ophthalmology 253–262 [PubMed: 17270675]
  170. Klein R, Meuer SM, Knudtson MD et al. (2008) The epidemiology of retinal reticular drusen American journal of ophthalmology Am J Ophthalmol 317–326 [PMC free article: PMC2258433] [PubMed: 18045568]
  171. Klein R, Meuer SM, Myers CE et al. (2014) Harmonizing the classification of age-related macular degeneration in the three-continent AMD consortium Ophthalmic epidemiology 21 (1) 14–23 [PMC free article: PMC4029416] [PubMed: 24467558]
  172. Klein R, Knudtson MD, Cruickshanks KJ et al. (2008) Further observations on the association between smoking and the long-term incidence and progression of age-related macular degeneration: the Beaver Dam Eye Study Archives of ophthalmology (Chicago, Ill.: 1960) 115–121 [PubMed: 18195228]
  173. Klein R, Cruickshanks KJ, Myers CE et al. (2013) The relationship of atherosclerosis to the 10-year cumulative incidence of age-related macular degeneration: the Beaver Dam studies Ophthalmology 1012–1019 [PMC free article: PMC3646961] [PubMed: 23399375]
  174. Knudtson MD, Klein R, Klein BE (2006) Physical activity and the 15-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study Br.J.Ophthalmol. 1461–1463 [PMC free article: PMC1857544] [PubMed: 17077116]
  175. Kodjikian L, Souied EH, Mimoun G et al. (2013) Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial Ophthalmology 120 (11) 2300–2309 [PubMed: 23916488]
  176. Koh A, Lee WK, Chen LJ et al. (2012) EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy Retina 32 1453–1464 [PubMed: 22426346]
  177. Krebs I, Vecsei M, V et al. (2013) Comparison of Ranibizumab monotherapy versus combination of Ranibizumab with photodynamic therapy with neovascular age-related macular degeneration Acta Opthalmologica 91 e178–e183 [PubMed: 23241227]
  178. Krebs I, Schmetterer L, Boltz A et al. (2013) A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration British Journal of Ophthalmology 97 (3) 266–271 [PubMed: 23292928]
  179. Kucukerdonmez C, Gelisken F, Yoeruek E et al. (2015) Switching intravitreal anti-VEGF treatment in neovascular age-related macular degeneration Eur J Ophthalmol 25 51–56 [PubMed: 24980110]
  180. Kumar N, Marsiglia M, Mrejen S et al. (2013) Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration Retina 33 1605–1612 [PubMed: 23549101]
  181. Kuppermann BD, Goldstein M, Maturi RK et al. (2015) Dexamethasone Intravitreal Implant as Adjunctive Therapy to Ranibizumab in Neovascular Age-Related Macular Degeneration: A Multicenter Randomized Controlled Trial Ophthalmologica 234 40–54 [PubMed: 26088793]
  182. Larsen M, Schmidt-Erfurth U, Lanzetta P et al. (2012) Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results Ophthalmology 119 992–1000 [PubMed: 22424834]
  183. Lawrenson JG, Evans JR (2015) Omega 3 fatty acids for preventing or slowing the eration The Cochrane Library [PMC free article: PMC7087473] [PubMed: 25856365]
  184. Lazic R, Gabric N (2007) Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration Ophthalmology 114 1179–1185 [PubMed: 17544776]
  185. Lechanteur Yara TE, van d, V, Johannes PH et al. (2012) Genetic, behavioral, and sociodemographic risk factors for second eye progression in age-related macular degeneration Invest Ophthalmol Vis Sci 5846–5852 [PubMed: 22815349]
  186. Li B, Powell AM, Hooper PL et al. (2015) Prospective evaluation of teleophthalmology in screening and recurrence monitoring of neovascular age-related macular degeneration: a randomized clinical trial JAMA Ophthalmology 133 (3) 276–282 [PubMed: 25473945]
  187. Li X, Hu Y, Sun X et al. (2012) Bevacizumab for neovascular age-related macular degeneration in China Ophthalmology 119 (10) 2087–2093 [PubMed: 22818896]
  188. Lim JH, Wickremasinghe SS, Xie J et al. (2012) Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration American Journal of Ophthalmology 153 (4) 678–86, 686 [PMC free article: PMC4869322] [PubMed: 22245460]
  189. Lim JY, Lee SY, Kim JG et al. (2012) Intravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 50 years or older: 1-year results of a prospective clinical study Acta Opthalmologica 90 61–67 [PubMed: 20337606]
  190. Lim JI, Labree L, Nichols T et al. (2002) Comparison of nonmydriatic digitized video fundus images with standard 35-mm slides to screen for and identify specific lesions of age-related macular degeneration Retina 22 (1) 59–64 [PubMed: 11884880]
  191. Little HL, Showman JM, Brown BW (1997) A pilot randomized controlled study on the effect of laser photocoagulation of confluent soft macular drusen Ophthalmology 104 (4) 623–631 [PubMed: 9111254]
  192. Lushchyk T, Amarakoon S, Martinez-Ciriano J et al. (2013) Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of injections every 4 weeks, 6 weeks and 8 weeks Acta ophthalmologica 91 (6) e456–e461 [PubMed: 23773796]
  193. Maberley DAL, Isbister C, Mackenzie P et al. (2005) An evaluation of photographic screening for neovascular age-related macular degeneration Eye 19 (6) 611–616 [PubMed: 15184945]
  194. Macaskill P, Gatsonis C, Deeks J et al. (2010) Cochrane handbook for systematic reviews of diagnostic test accuracy Version 0.9.0. London: The Cochrane Collaboration
  195. Maguire MG, Alexander J, Fine SL (2008) Characteristics of choroidal neovascularization in the complications of age-related macular degeneration prevention trial Ophthalmology 115 (9) 1468–73, 1473 [PubMed: 18486222]
  196. Maguire MG, Bressler SB, Bresskr NM et al. (1997) Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration Archives of Ophthalmology 115 (6) 741–747 [PubMed: 9194725]
  197. Maguire MG, Ying GS, McCannel CA et al. (2009) Statin use and the incidence of advanced age-related macular degeneration in the Complications of Age-related Macular Degeneration Prevention Trial Ophthalmology 116 (12) 2381–2385 [PMC free article: PMC2787900] [PubMed: 19850347]
  198. Mahmood S, Roberts SA, Aslam TM et al. (2015) Routine versus as-needed bevacizumab with 12-weekly assessment intervals for neovascular age-related macular degeneration: 92-week results of the gman trial Ophthalmology 122 (7) 1348–1355 [PubMed: 25892016]
  199. Major JC, Jr., Wykoff CC, Croft DE, Wang R, Mariani AF, Lehmann AE et al. Aflibercept for pigment epithelial detachment for previously treated neovascular age-related macular degeneration. Can J Ophthalmol 2015; 50(5):373–377 [PubMed: 26455973]
  200. Maksys S, Richter-Muksch S, Weingessel B, Vecsei-Marlovits PV. Short-term effect of aflibercept on visual acuity and central macular thickness in patients not responding to ranibizumab and bevacizumab. Wien Klin Wochenschr 2017; 129(9–10):351–357 [PubMed: 27550436]
  201. Mantel I, Gianniou C, Dirani A (2016) Conversion to Aflibercept Therapy Versus Continuing with Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration Dependent on Monthly Ranibizumab Treatment Retina 36 53–58 [PubMed: 26166797]
  202. Markun S, Dishy A, Neuner-Jehle S et al. (2015) The Chronic Care for Wet Age Related Macular Degeneration (CHARMED) Study: A Randomized Controlled Trial PLoS ONE [Electronic Resource] 10 (11) e0143085- [PMC free article: PMC4646575] [PubMed: 26569501]
  203. Martin DF, Maguire MG, Fine SL et al. (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology 119 (7) 1388–1398 [PMC free article: PMC3389193] [PubMed: 22555112]
  204. Mathew R, Pefkianaki M, Kopsachilis N et al. (2013) Correlation of fundus fluorescein angiography and spectral-domain optical coherence tomography in identification of membrane subtypes in neovascular age-related macular degeneration Ophthalmologica 231 (3) 153–159 [PubMed: 24217293]
  205. McCloud C, Khadka J, Gilhotra JS et al. (2014) Divergence in the lived experience of people with macular degeneration Optometry & Vision Science 91 966–974 [PubMed: 24978869]
  206. McCloud C, Lake S (2015) Understanding the patient’s lived experience of neovascular age-related macular degeneration: a qualitative study Eye 29 (12) 1561–1569 [PMC free article: PMC5129784] [PubMed: 26381099]
  207. McCrone PR, Dhanasiri S, Patel A, et al. (2008) Paying the price: the cost of mental health care in England to 2026. King’s Fund.
  208. McKibbin M, Devonport H, Gale R et al. (2015) Aflibercept in wet AMD beyond the first year of treatment: recommendations by an expert roundtable panel Eye (London, England) 2015/07/15 S1–s11 [PMC free article: PMC4506328] [PubMed: 26156564]
  209. Meads C, Moore D (2001) The clinical effectiveness and cost utility of photodynamic therapy for age-related macular degeneration: REP Committee draft report with amendments Birmingham: Regional Evaluation Panel (REP)
  210. Meads C, Hyde C (2003) What is the cost of blindness? British Journal of Ophthalmology 87 (10) 1201–1204 [PMC free article: PMC1920795] [PubMed: 14507746]
  211. Meads C, Salas C, Roberts T et al. (2003) Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation [PubMed: 12709292]
  212. Menon G, Chandran M, Sivaprasad S et al. (2013) Is it necessary to use three mandatory loading doses when commencing therapy for neovascular age-related macular degeneration using bevacizumab?(BeMOc Trial) Eye 27 (8) 959–963 [PMC free article: PMC3740324] [PubMed: 23743535]
  213. Messori A (2017) Controversies in Using Off-Label Intravitreous Bevacizumab for Patients With Diabetic Macular Edema JAMA Ophthalmology [PubMed: 28152122]
  214. Mitchell J, Bradley P, Anderson SJ et al. (2002) Perceived quality of health care in macular disease: a survey of members of the Macular Disease Society British Journal of Ophthalmology 86 777–781 [PMC free article: PMC1771190] [PubMed: 12084749]
  215. Mitchell P, Korobelnik JF, Lanzetta P et al. (2010) Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials The British journal of ophthalmology 2009/05/16 2–13 [PubMed: 19443462]
  216. Moisseiev E, Katz G, Moisseiev J et al. (2015) SWITCHING TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION FROM BEVACIZUMAB TO RANIBIZUMAB: Who is Likely to Benefit From the Switch? Retina 35 1323–1330 [PubMed: 26102434]
  217. Mokwa NF, Ristau T, Keane PA et al. (2013) Grading of age-related macular degeneration: comparison between color fundus photography, fluorescein angiography, and spectral domain optical coherence tomography Journal of ophthalmology 2013 [PMC free article: PMC3665260] [PubMed: 23762528]
  218. Mowatt G, Hern+índez R, Castillo M et al. (2014) Optical coherence tomography for the diagnosis, monitoring and guiding of treatment for neovascular age-related macular degeneration: a systematic review and economic evaluation Health Technology Assessment [PMC free article: PMC4780940] [PubMed: 25436855]
  219. Muen WJ, Hewick SA (2011) Quality of optometry referrals to neovascular age-related macular degeneration clinic: a prospective study JRSM Short Reports 2 (8) 64- [PMC free article: PMC3166265] [PubMed: 21912730]
  220. Muether PS, Hermann MM, Koch K et al. (2011) Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity Graefes Archive for Clinical & Experimental Ophthalmology 249 (5) 633–637 [PubMed: 20865421]
  221. Muether PS, Hoerster R, Hermann MM et al. (2013) Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration Graefes Archive for Clinical & Experimental Ophthalmology 251 (2) 453–458 [PubMed: 22573410]
  222. Murray IJ, Makridaki M, van der Veen RL et al. (2013) Lutein Supplementation over a One-Year Period in Early AMD Might Have a Mild Beneficial Effect on Visual Acuity: The CLEAR StudyEffect of Lutein Supplementation on Visual Acuity Investigative ophthalmology & visual science 54 (3) 1781–1788 [PubMed: 23385792]
  223. Narayan DS, Muecke J (2015) Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab Indian J Ophthalmol 63 832–836 [PMC free article: PMC4730694] [PubMed: 26669334]
  224. National Institute for Clinical Excellence (2003) Guidance on the use of photodynamic therapy for age-related macular degeneration. NICE technology appraisal guidance (TA68)
  225. National Institute for Health and Care Excellence (2013) Aflibercept solution for injection for treating wet age-related macular degeneration. NICE technology appraisal guidance (TA294)
  226. National Institute for Health and Care Excellence (2014) Developing NICE guidelines: the manual [PubMed: 26677490]
  227. National Institute for Health and Care Excellence (2015) Aflibercept for treating diabetic macular oedema. NICE technology appraisal guidance (TA346)
  228. National Institute for Health and Care Excellence (2016) Cardiovascular disease: risk assessment and reduction, including lipid modification. NICE guideline (CG181) [PubMed: 31841282]
  229. National Institute for Health and Clinical Excellence (2008) Ranibizumab and pegaptanib for the treatment of age-related macular degeneration. NICE technology appraisal guidance (TA155)
  230. National Institute for Health and Clinical Excellence (2011) Ranibizumab for the treatment of diabetic macular oedema. NICE technology appraisal guidance (TA237)
  231. Neubauer AS, Holz FG, Sauer S et al. (2010) Cost-effectiveness of ranibizumab for the treatment of neovascular age-related macular degeneration in Germany: Model analysis from the perspective of Germany’s statutory health insurance system Clinical therapeutics 32 (7) 1343–1356 [PubMed: 20678682]
  232. Newsome DA, Swartz M, Leone NC et al. (1988) Oral zinc in macular degeneration Archives of Ophthalmology 106 (2) 192–198 [PubMed: 3277606]
  233. NHS Business Services Authority, NHS Prescription Services (2017) National Health Service Drug Tariff for England and Wales
  234. NHS Digital (2015) Hospital outpatient activity - 2014-15: main procedure of intervention
  235. NHS Digital (2015) Hospital episode statistics, admitted patient care - England, 2014-15: procedures and interventions
  236. Nixon DR, Flinn NA. Evaluation of contrast sensitivity and other visual function outcomes in neovascular age-related macular degeneration patients after treatment switch to aflibercept from ranibizumab. Clin Ophthalmol 2017; 11:715–721 [PMC free article: PMC5403004] [PubMed: 28458510]
  237. Nomura Y, Yanagi Y (2015) Intravitreal aflibercept for ranibizumab-resistant exudative age-related macular degeneration with choroidal vascular hyperpermeability Jpn J Ophthalmol 59 261–265 [PubMed: 25983109]
  238. Nunes RP, Nobrega MJ, De N et al. (2010) Causes of interruption of bevacizumab therapy in age-related macular degeneration Arquivos Brasileiros de Oftalmologia 73 146–149 [PubMed: 20549043]
  239. Office for National Statistics (2017) National life tables, UK: 2013-2015
  240. Oishi A, Kojima H, Mandai M et al. (2013) Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results American Journal of Ophthalmology 156 (4) 644–651 [PubMed: 23876867]
  241. Oliver-Fernandez A, Bakal J, Segal S et al. (2005) Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration Canadian Journal of Ophthalmology 40 (3) 313–319 [PubMed: 15947801]
  242. Olk RJ, Friberg TR, Stickney KL et al. (1999) Therapeutic benefits of infrared (810-nm) diode laser macular grid photocoagulation in prophylactic treatment of nonexudative age-related macular degeneration: two-year results of a randomized pilot study Ophthalmology 106 (11) 2082–2090 [PubMed: 10571341]
  243. Olk RJ, Peralta E, Gierhart DL et al. (2015) Triple combination therapy and zeaxanthin for the treatment of neovascular age-related macular degeneration: an interventional comparative study and cost-effectiveness analysis International Journal of Retina and Vitreous 1 (1) 1- [PMC free article: PMC5088486] [PubMed: 27847615]
  244. Olsen TW, Feng X, Kasper TJ et al. (2004) Fluorescein angiographic lesion type frequency in neovascular age-related macular degeneration Ophthalmology 111 (2) 250–255 [PubMed: 15019371]
  245. Owens SL, Bunce C, Brannon AJ et al. (2003) Prophylactic laser treatment appears to promote choroidal neovascularisation in high-risk ARM: results of an interim analysis Eye 17 (5) 623–627 [PubMed: 12855972]
  246. Padnick-Silver L, Weinberg AB, Lafranco FP et al. (2012) Pilot study for the detection of early exudative age-related macular degeneration with optical coherence tomography Retina 32 (6) 1045–1056 [PubMed: 22186740]
  247. Panchmatia HR, Clements KM, Hulbert E et al. (2016) Aflibercept vs. Ranibizumab: cost–effectiveness of treatment for wet age–related macular degeneration in Sweden Acta ophthalmologica [PubMed: 27061020]
  248. Parodi MB, Toto L, Mastropasqua L et al. (2004) Prismatic correction in patients affected by age-related macular degeneration Clinical Rehabilitation 18 (7) 828–832 [PubMed: 15573840]
  249. Patel JJ, Mendes MA, Bounthavong M et al. (2012) Cost–utility analysis bevacizumab versus ranibizumab in neovascular age–related macular degeneration using a Markov model Journal of evaluation in clinical practice 18 (2) 247–255 [PubMed: 20846318]
  250. Patel KH, Chow CC, Rathod R et al. (2013) Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab Eye 27 663–667 [PMC free article: PMC3650278] [PubMed: 23558214]
  251. Perlee LT, Bansal AT, Gehrs K et al. (2013) Inclusion of genotype with fundus phenotype improves accuracy of predicting choroidal neovascularization and geographic atrophy Ophthalmology 120 (9) 1880–1892 [PMC free article: PMC3695024] [PubMed: 23523162]
  252. Piermarocchi S, Saviano S, Parisi V et al. (2012) Carotenoids in Age-related Maculopathy Italian Study (CARMIS): two-year results of a randomized study European Journal of Ophthalmology 22 (2) 216- [PubMed: 22009916]
  253. Pinheiro-Costa J, Costa JM, Beato JN et al. (2015) Switch to Aflibercept in the Treatment of Neovascular AMD: One-Year Results in Clinical Practice Ophthalmologica 233 155–161 [PubMed: 25896317]
  254. Pirbhai A, Sheidow T, Hooper P (2005) Prospective evaluation of digital non-stereo color fundus photography as a screening tool in age-related macular degeneration American Journal of Ophthalmology 139 (3) 455–461 [PubMed: 15767053]
  255. Piri N, Ahmadieh H, Taei R et al. (2014) Photodynamic Therapy and Intravitreal Bevacizumab with Versus without Triamcinolone for Neovascular Age-related Macular Degeneration; a Randomized Clinical Trial Journal of Ophthalmic & Vision Research 9 469–477 [PMC free article: PMC4329708] [PubMed: 25709773]
  256. Raftery J, Clegg A, Jones J et al. (2007) Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness British Journal of Ophthalmology 91 (9) 1244–1246 [PMC free article: PMC1954941] [PubMed: 17431015]
  257. Ranchod TM, Ray SK, Daniels SA et al. (2013) LuceDex: a prospective study comparing ranibizumab plus dexamethasone combination therapy versus ranibizumab monotherapy for neovascular age-related macular degeneration Retina 33 1600–1604 [PubMed: 23549100]
  258. Rasmussen A, Brandi S, Fuchs J et al. (2015) Visual outcomes in relation to time to treatment in neovascular age-related macular degeneration Acta Opthalmologica 93 (7) 616–620 [PubMed: 26073051]
  259. Rasul A, Subhi Y, Sorensen TL et al. (2016) Non-Physician delivered intravitreal injection service is feasible and safe - A systematic review Danish Medical Journal 63 (5) no- [PubMed: 27127016]
  260. Rauch R, Weingessel B, Maca SM et al. (2012) Time to first treatment: The significance of early treatment of exudative age-related macular degeneration Retina 32 (7) 1260–1264 [PubMed: 22186738]
  261. Real JP, Luna JD, Urrets-Zavalia JA et al. (2013) Accessibility as a conditioning factor in treatment for exudative age-related macular degeneration European Journal of Ophthalmology 23 (6) 857–864 [PubMed: 23661541]
  262. Reeves BC, Harper RA, Russell WB (2004) Enhanced low vision rehabilitation for people with age related macular degeneration: a randomised controlled trial British Journal of Ophthalmology 88 (11) 1443–1449 [PMC free article: PMC1772403] [PubMed: 15489491]
  263. Reeves BC, Scott LJ, Taylor J et al. (2016) Effectiveness of Community versus Hospital Eye Service follow-up for patients with neovascular age-related macular degeneration with quiescent disease (ECHoES): a virtual non-inferiority trial BMJ Open 6 (7) e010685- [PMC free article: PMC4947830] [PubMed: 27401357]
  264. Regillo CD, Busbee BG, Ho AC et al. (2015) Baseline Predictors of 12-Month Treatment Response to Ranibizumab in Patients With Wet Age-Related Macular Degeneration American Journal of Ophthalmology 160 (5) 1014–1023 [PubMed: 26231305]
  265. Regillo CD, Brown DM, Abraham P et al. (2008) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1 American Journal of Ophthalmology 145 (2) 239–248 [PubMed: 18222192]
  266. Rein DB, Saaddine JB, Wittenborn JS et al. (2007) Cost-effectiveness of vitamin therapy for age-related macular degeneration Ophthalmology 114 (7) 1319–1326 [PubMed: 17320962]
  267. Reynolds R, Rosner B, Seddon JM (2013) Dietary omega-3 fatty acids, other fat intake, genetic susceptibility, and progression to incident geographic atrophy Ophthalmology 1020–1028 [PMC free article: PMC3758110] [PubMed: 23481534]
  268. Richer S (1996) Multicenter ophthalmic and nutritional age-related macular degeneration study--part 2: antioxidant intervention and conclusions Journal of the American Optometric Association 67 (1) 30–49 [PubMed: 8825017]
  269. Richer S, Stiles W, Statkute L et al. (2004) Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial) Optometry-Journal of the American Optometric Association 75 (4) 216–229 [PubMed: 15117055]
  270. Rofagha S, Bhisitkul RB, Boyer DS et al. (2013) Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP) Ophthalmology 120 (11) 2292–2299 [PubMed: 23642856]
  271. Rosenfeld PJ, Brown DM, Heier JS et al. (2006) Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 1419–1431 [PubMed: 17021318]
  272. Rosenfeld PJ, Brown DM, Heier JS et al. (2006) Ranibizumab for neovascular age-related macular degeneration New England Journal of Medicine 355 (14) 1419–1431 [PubMed: 17021318]
  273. Rovner BW, Casten RJ, Hegel MT et al. (2007) Preventing depression in age-related macular degeneration Archives of General Psychiatry 64 (8) 886–892 [PubMed: 17679633]
  274. Rovner BW, Casten RJ, Hegel MT et al. (2013) Improving function in age-related macular degeneration: a randomized clinical trial Ophthalmology 120 (8) 1649–1655 [PMC free article: PMC3737407] [PubMed: 23642378]
  275. Rovner BW, Casten RJ, Hegel MT et al. (2014) Low vision depression prevention trial in age-related macular degeneration: a randomized clinical trial Ophthalmology 121 (11) 2204–2211 [PMC free article: PMC4253064] [PubMed: 25016366]
  276. Sacu S, Michels S, Prager F et al. (2009) Randomised clinical trial of intravitreal Avastin vs photodynamic therapy and intravitreal triamcinolone: long-term results Eye 23 (12) 2223–2227 [PubMed: 19169239]
  277. Saito M, Kano M, Itagaki K et al. (2014) Switching to intravitreal aflibercept injection for polypoidal choroidal vasculopathy refractory to ranibizumab Retina 34 2192–2201 [PubMed: 25077530]
  278. Saito M, Kano M, Itagaki K et al. (2016) Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection Jpn J Ophthalmol 60 35–41 [PubMed: 26350229]
  279. Salinas-Alaman A, Garcia-Layana A, Maldonado MJ et al. (2005) Using optical coherence tomography to monitor photodynamic therapy in age related macular degeneration American Journal of Ophthalmology 140 (1) 23–28 [PubMed: 15922284]
  280. Sallet G, Lafaut BA, De Laey JJ (1996) Indocyanine green angiography and age-related serous pigment epithelial detachment Graefe’s archive for clinical and experimental ophthalmology 234 (1) 25–33 [PubMed: 8750847]
  281. Sandberg MA, Weiner A, Miller S et al. (1998) High-risk characteristics of fellow eyes of patients with unilateral neovascular age-related macular degeneration Ophthalmology 441–447 [PubMed: 9499774]
  282. Sandhu SS, Talks SJ (2005) Correlation of optical coherence tomography, with or without additional colour fundus photography, with stereo fundus fluorescein angiography in diagnosing choroidal neovascular membranes British Journal of Ophthalmology 89 (8) 967–970 [PMC free article: PMC1772793] [PubMed: 16024845]
  283. Sarao V, Parravano M, Veritti D et al. (2016) Intravitreal Aflibercept for Choroidal Neovascularization Due to Age-Related Macular Degeneration Unresponsive to Ranibizumab Therapy Retina 36 (4) 770–777 [PubMed: 26398691]
  284. Scanlon PH, Loftus J, Starita C et al. (2015) The use of weighted Life scores in people with diabetic macular oedema at baseline in a randomized clinical trial Diabetic Medicine 32 (1) 97–101 [PMC free article: PMC4307641] [PubMed: 25251842]
  285. Schauwvlieghe AME, Dijkman G, Hooymans JM et al. (2016) Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age-related macular degeneration. The BRAMD study PLoS One 11 (5) no- [PMC free article: PMC4874598] [PubMed: 27203434]
  286. Schmidt-Erfurth U, Eldem B, Guymer R et al. (2011) Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study Ophthalmology 118 (5) 831–839 [PubMed: 21146229]
  287. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF et al. (2014) Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration: Ninety-Six-eek Results of the VIEW Studies Ophthalmology 121 (1) 193–201 [PubMed: 24084500]
  288. Schmier JK, Halpern MT, Covert D et al. (2006) Impact of visual impairment on use of caregiving by individuals with age-related macular degeneration Retina 26 (9) 1056–1062 [PubMed: 17151494]
  289. Schwartz AL, Meek PM, Nail LM et al. (2002) Measurement of fatigue: determining minimally important clinical differences Journal of clinical epidemiology 55 (3) 239–244 [PubMed: 11864794]
  290. Seddon JM, Sharma S, Adelman RA (2006) Evaluation of the clinical age-related maculopathy staging system Ophthalmology 113 (2) 260–266 [PubMed: 16458093]
  291. Seddon JM, Cote J, Davis N et al. (2003) Progression of age-related macular degeneration: association with body mass index, waist circumference, and waist-hip ratio Archives of ophthalmology (Chicago, Ill.: 1960) 785–792 [PubMed: 12796248]
  292. Seddon JM, Cote J, Rosner B (2003) Progression of age-related macular degeneration: association with dietary fat, transunsaturated fat, nuts, and fish intake Archives of ophthalmology (Chicago, Ill.: 1960) 1728–1737 [PMC free article: PMC8443211] [PubMed: 14662593]
  293. Seddon JM, Reynolds R, Yu Y et al. (2011) Risk models for progression to advanced age-related macular degeneration using demographic, environmental, genetic, and ocular factors Ophthalmology 2203–2211 [PMC free article: PMC4097877] [PubMed: 21959373]
  294. Seddon JM, Reynolds R, Yu Y et al. (2013) Validation of a prediction algorithm for progression to advanced macular degeneration subtypes JAMA Ophthalmol 448–455 [PMC free article: PMC6547827] [PubMed: 23411794]
  295. Seddon JM, Silver RE, Kwong M et al. (2015) Risk Prediction for Progression of Macular Degeneration: 10 Common and Rare Genetic Variants, Demographic, Environmental, and Macular Covariates Invest Ophthalmol Vis Sci 2192–2202 [PMC free article: PMC4405097] [PubMed: 25655794]
  296. Semeraro F, Russo A, Delcassi L et al. (2015) Treatment of Exudative Age-Related Macular Degeneration with Ranibizumab Combined with Ketorolac Eyedrops or Photodynamic Therapy Retina 35 1547–1554 [PubMed: 25784358]
  297. Shaikh AH, Toussaint BW, Miller DM et al. (2015) Cost comparison of intravitreal aflibercept with bevacizumab and ranibizumab for the treatment of wet age-related macular degeneration Ophthalmic Surg Lasers Imaging Retina 46 62–66 [PubMed: 25559511]
  298. Sharma S, Brown GC, Brown MM et al. (2000) The cost-effectiveness of grid laser photocoagulation for the treatment of diabetic macular edema: results of a patient-based cost-utility analysis Current opinion in ophthalmology 11 (3) 175–179 [PubMed: 10977223]
  299. Shea BJ, Grimshaw JM, Wells GA et al. (2007) Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews BMC medical research methodology 7 (1) 10- [PMC free article: PMC1810543] [PubMed: 17302989]
  300. Shiragami C, Ono A, Kobayashi M et al. (2014) Effect of switching therapy to pegaptanib in eyes with the persistent cases of exudative age-related macular degeneration 93 no- [PMC free article: PMC4616293] [PubMed: 25319441]
  301. Simcock P, Kingett B, Mann N et al. (2014) A safety audit of the first 10 000 intravitreal ranibizumab injections performed by nurse practitioners Eye (Basingstoke) 28 (10) 1161–1164 [PMC free article: PMC4194327] [PubMed: 25033899]
  302. Smith DH, Fenn P, Drummond M (2004) Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case British Journal of Ophthalmology 88 (9) 1107–1112 [PMC free article: PMC1772332] [PubMed: 15317697]
  303. Smith HJ, Dickinson CM, Cacho I et al. (2005) A randomized controlled trial to determine the effectiveness of prism spectacles for patients with age-related macular degeneration Archives of Ophthalmology 123 (8) 1042–1050 [PubMed: 16087836]
  304. Solomon SD, Lindsley K, Vedula SS et al. (2014) Anti–vascular endothelial growth factor for neovascular age–related macular degeneration The Cochrane Library [PMC free article: PMC4270425] [PubMed: 25170575]
  305. Souied EH, Delcourt C+, Querques G et al. (2013) Oral docosahexaenoic acid in the prevention of exudative age-related macular degeneration: the Nutritional AMD Treatment 2 study Ophthalmology 120 (8) 1619–1631 [PubMed: 23395546]
  306. Stein JD, VanderBeek BL, Talwar N et al. (2011) Rates of nonexudative and exudative age-related macular degeneration among Asian American ethnic groups Invest Ophthalmol Vis Sci 6842–6848 [PMC free article: PMC3176030] [PubMed: 21778274]
  307. Stein JD, Newman-Casey PA, Mrinalini T et al. (2014) Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration Ophthalmology 121 (4) 936–945 [PMC free article: PMC4109727] [PubMed: 24405740]
  308. Steinbrook R (2006) The price of sight–ranibizumab, bevacizumab, and the treatment of macular degeneration New England Journal of Medicine 355 (14) 1409–1412 [PubMed: 17021315]
  309. Stur M, Tittl M, Reitner A et al. (1996) Oral zinc and the second eye in age-related macular degeneration Investigative ophthalmology & visual science 37 (7) 1225–1235 [PubMed: 8641826]
  310. Submacular Surgery Trials Research Group, Solomon, Jefferys SD et al. (2009) Risk factors for second eye progression to advanced age-related macular degeneration: SST report No. 21 Submacular Surgery Trials Research Group Retina (Philadelphia, Pa.) 1080–1090 [PubMed: 19734762]
  311. Submacular Surgery Trials Research Group (2009) Risk factors for second eye progression to advanced age-related macular degeneration: SST report No. 21 Submacular Surgery Trials Research Group Retina 29 (8) 1080–1090 [PubMed: 19734762]
  312. Subramanian ML, Abedi G, Ness S et al. (2010) Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial Eye 24 (11) 1708–1715 [PubMed: 20885427]
  313. Sullivan PW, Slejko JF, Sculpher MJ et al. (2011) Catalogue of EQ-5D scores for the United Kingdom Medical Decision Making 31 (6) 800–804 [PubMed: 21422468]
  314. Sunness JS, Gonzalez-Baron J, Applegate CA et al. (1999) Enlargement of atrophy and visual acuity loss in the geographic atrophy form of age-related macular degeneration Ophthalmology 106 (9) 1768–1779 [PubMed: 10485549]
  315. Takahashi H, Ohkubo Y, Sato A et al. (2015) Relationship between visual prognosis and delay of intravitreal injection of ranibizumab when treating agerelated macular degeneration Retina 35 (7) 1331–1338 [PubMed: 25719984]
  316. Talks J, Koshy Z, Chatzinikolas K (2007) Use of optical coherence tomography, fluorescein angiography and indocyanine green angiography in a screening clinic for wet age-related macular degeneration British Journal of Ophthalmology 91 (5) 600–601 [PMC free article: PMC1954754] [PubMed: 17151058]
  317. Tao Y, Jonas JB (2010) Intravitreal bevacizumab combined with intravitreal triamcinolone for therapy-resistant exudative age-related macular degeneration J Ocul Pharmacol Ther 26 207–212 [PubMed: 20415625]
  318. Tappenden P, Chilcott J, Brennan A et al. (2012) Whole disease modeling to inform resource allocation decisions in cancer: a methodological framework Value in Health 15 (8) 1127–1136 [PubMed: 23244816]
  319. Tappenden P, Chilcott J, Brennan A et al. (2013) Using whole disease modeling to inform resource allocation decisions: economic evaluation of a clinical guideline for colorectal cancer using a single model Value in Health 16 (4) 542–553 [PubMed: 23796288]
  320. The Royal College of Ophthalmologists (2013) age-related macular degeneration: guidelines for management. London:
  321. Thompson AC, Thompson MO, Young DL et al. (2015) Barriers to Follow-Up and Strategies to Improve Adherence to Appointments for Care of Chronic Eye Diseases Investigative ophthalmology & visual science 56 4324–4331 [PubMed: 26176869]
  322. Thorell MR, Nunes RP, Chen GW et al. (2014) Response to aflibercept after frequent retreatment with bevacizumab or ranibizumab in eyes with neovascular AMD Ophthalmic Surg Lasers Imaging Retina 45 526–533 [PubMed: 25423632]
  323. Tiosano L, Segal O, Mathalone N, Pollack A, Ehrlich R, Klemperer I et al. Aflibercept as a Second Line Therapy for Neovascular Age Related Macular Degeneration in Israel (ASLI) study. Eye (Lond) 2017; 31(6):890–898 [PMC free article: PMC5518842] [PubMed: 28211882]
  324. Treatment of Age-related Macular Degeneration With Photodynamic Therapy Study Group (1999) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report 1 Archives of Ophthalmology 117 (10) 1329- [PubMed: 10532441]
  325. Tschuor P, Pilly B, Venugopal D et al. (2013) Optimising assessment intervals improves visual outcomes in ranibizumab-treated age-related neovascular degeneration: using the stability phase as a benchmark Graefes Archive for Clinical & Experimental Ophthalmology 251 (10) 2327–2330 [PubMed: 23591940]
  326. Tufail A, Patel PJ, Egan C et al. (2010) Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study Bmj 340 c2459- [PubMed: 20538634]
  327. Tufail A, Xing W, Johnston R et al. (2014) The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections Ophthalmology 121 (5) 1092–1101 [PubMed: 24461586]
  328. Vallance JH, Johnson B, Majid MA et al. (2010) A randomised prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration Eye 24 1561–1567 [PubMed: 20577273]
  329. Van dM, A, Sandhu SS et al. (2006) Correlation of optical coherence tomography and fundus fluorescein angiography following photodynamic therapy for choroidal neovascular membranes British Journal of Ophthalmology 90 (3) 304–306 [PMC free article: PMC1856971] [PubMed: 16488950]
  330. van LR, Chakravarthy U, Vingerling JR et al. (2003) Grading of age-related maculopathy for epidemiological studies: is digital imaging as good as 35-mm film? Ophthalmology 110 (8) 1540–1544 [PubMed: 12917169]
  331. van LR, Boekhoorn S, Vingerling JR et al. (2005) Dietary intake of antioxidants and risk of age-related macular degeneration JAMA 3101–3107 [PubMed: 16380590]
  332. van V, M E, de S et al. (2006) Added value of OCT in evaluating the presence of leakage in patients with age-related macular degeneration treated with PDT Graefes Archive for Clinical & Experimental Ophthalmology 244 (9) 1119–1123 [PubMed: 16523305]
  333. VanderBeek BL, Zacks DN, Talwar N et al. (2011) Racial differences in age-related macular degeneration rates in the United States: a longitudinal analysis of a managed care network Am J Ophthalmol 273–282 [PMC free article: PMC3143259] [PubMed: 21696700]
  334. Varano M, Eter N, Winyard S et al. (2015) Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey Clinical Ophthalmology 9 2243–2250 [PMC free article: PMC4671808] [PubMed: 26664038]
  335. Vaze A, Fraser-Bell S, Gillies M (2014) Reasons for discontinuation of intravitreal vascular endothelial growth factor inhibitors in neovascular age-related macular degeneration Retina 34 1774–1778 [PubMed: 24837049]
  336. Verteporfin In Photodynamic Therapy Study (2001) Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization–verteporfin in photodynamic therapy report 2 American Journal of Ophthalmology 131 (5) 541–560 [PubMed: 11336929]
  337. Virgili G, Michelessi M, Parodi MB et al. (2015) Laser treatment of drusen to prevent progression to advanced age–ÇÉrelated macular degeneration The Cochrane Library [PMC free article: PMC4733883] [PubMed: 26493180]
  338. Visudyne in Minimally Classic Choroidal Neovascularization Study Group (2005) Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial Archives of Ophthalmology 123 (4) 448- [PubMed: 15824216]
  339. Vogel RN, Davis DB, Kimura BH et al. (2016) Neovascular age-related macular degeneration with advanced visual loss treated with anti-vascular endothelial growth factor therapy: Clinical Outcome and Prognostic Indicators Retina no- [PubMed: 27429385]
  340. Vottonen P, Kankaanp E (2016) Cost-effectiveness of treating wet age-related macular degeneration at the Kuopio University Hospital in Finland based on a two-eye Markov transition model Acta ophthalmologica 94 (7) 652–656 [PubMed: 27481048]
  341. Vukicevic M, Fitzmaurice K (2005) Rehabilitation strategies used to ameliorate the impact of centre field loss Visual Impairment Research 7 79–84
  342. Vukicevic M, Fitzmaurice K (2009) Eccentric viewing training in the home environment: can it improve the performance of dynamic self-care activities of daily living? Journal of visual impairment & blindness 103 (5) 277–290
  343. Vukicevic M, Heraghty J, Cummins R et al. (2016) Caregiver perceptions about the impact of caring for patients with wet age-related macular degeneration Eye 30 (3) 413–421 [PMC free article: PMC4791694] [PubMed: 26611848]
  344. Weingessel B, Mihaltz K, Vecsei-Marlovits P, V (2016) Predictors of 1-year visual outcome in OCT analysis comparing ranibizumab monotherapy versus combination therapy with PDT in exsudative age-related macular degeneration Wiener Klinische Wochenschrift 128 (15–16) 560–565 [PubMed: 25787216]
  345. Wilde C, Patel M, Lakshmanan A et al. (2015) The diagnostic accuracy of spectral-domain optical coherence tomography for neovascular age-related macular degeneration: a comparison with fundus fluorescein angiography Eye 29 (5) 602–610 [PMC free article: PMC4429282] [PubMed: 25907206]
  346. Williams PD, Callanan D, Solley W et al. (2012) A prospective pilot study comparing combined intravitreal ranibizumab and half-fluence photodynamic therapy with ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration Clinical ophthalmology (Auckland, N.Z.) 6 1519–1525 [PMC free article: PMC3460704] [PubMed: 23055673]
  347. Williams PT (2009) Prospective study of incident age-related macular degeneration in relation to vigorous physical activity during a 7-year follow-up Invest Ophthalmol Vis Sci 101–106 [PMC free article: PMC4090325] [PubMed: 18566466]
  348. Williams TA, Blyth CP (2011) Outcome of ranibizumab treatment in neovascular age related macula degeneration in eyes with baseline visual acuity better than 6/12 Eye 25 (12) 1617–1621 [PMC free article: PMC3234468] [PubMed: 21921947]
  349. Wilson HL, Schwartz DM, Bhatt HR et al. (2004) Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration Am J Ophthalmol 615–624 [PubMed: 15059698]
  350. Wolf-Schnurrbusch UEK, Zinkernagel MS, Munk MR et al. (2015) Oral Lutein Supplementation Enhances Macular Pigment Density and Contrast Sensitivity but Not in Combination With Polyunsaturated Fatty Acids PUFA May Lessen Lutein’s Effect on MPOD and CS Investigative ophthalmology & visual science 56 (13) 8069–8074 [PubMed: 26720458]
  351. Wong T, Chakravarthy U, Klein R et al. (2008) The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis Ophthalmology 115 (1) 116–126 [PubMed: 17675159]
  352. Wormald R, Evans JR, Smeeth LL et al. (2007) Photodynamic therapy for neovascular age–related macular degeneration The Cochrane Library [PubMed: 17636693]
  353. Writing committee for the UK age-related macular degeneration EMR User group (2014) The neovascular age-related macular degeneration database: Multicenter study of 92 976 ranibizumab injections: Report 1: Visual acuity manuscript no. 2013-568 Ophthalmology 121 (5) 1092–1101 [PubMed: 24461586]
  354. Wu B, Li J, Lin H et al. (2016) Different Strategies for the Treatment of Age-Related Macular Degeneration in China: An Economic Evaluation Journal of ophthalmology 2016 [PMC free article: PMC4855017] [PubMed: 27200183]
  355. Wykoff CC, Croft DE, Brown DM et al. (2015) Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-Year Results Ophthalmology 122 (12) 2514–2522 [PubMed: 26391465]
  356. Wykoff CC, Brown DM, Maldonado ME, Croft DE. Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial). Br J Ophthalmol 2014; 98(7):951–955 [PMC free article: PMC4078682] [PubMed: 24518078]
  357. Yanagi Y, Ueta T, Obata R et al. (2011) Utility values in Japanese patients with exudative age-related macular degeneration Japanese journal of ophthalmology 55 (1) 35–38 [PubMed: 21331690]
  358. Yanagi Y, Fukuda A, Barzey V et al. (2016) Cost-effectiveness of intravitreal aflibercept versus other treatments for wet age-related macular degeneration in Japan Journal of Medical Economics 1–9 [PubMed: 27701921]
  359. Ying GS, Huang J, Maguire MG et al. (2013) Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration Ophthalmology 120 (1) 122–129 [PMC free article: PMC3536921] [PubMed: 23047002]
  360. Yonekawa Y, Andreoli C, Miller JB et al. (2013) Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration Am J Ophthalmol 156 29–35 [PubMed: 23668679]
  361. Yuzawa M, Fujita K, Wittrup-Jensen K et al. (2015) Improvement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degeneration Ophthalmology 122 (3) 571–578 [PubMed: 25439429]
  362. Zarranz-Ventura J, Liew G, Johnston RL et al. (2014) The neovascular age-related macular degeneration database: report 2: incidence, management, and visual outcomes of second treated eyes Ophthalmology 121 (10) 1966–1975 [PubMed: 24953791]
  363. Zhu M, Chew JK, Broadhead GK et al. (2015) Intravitreal Ranibizumab for neovascular Age-related macular degeneration in clinical practice: five-year treatment outcomes Graefes Archive for Clinical & Experimental Ophthalmology 253 (8) 1217–1225 [PubMed: 25205618]
Copyright © NICE 2018.
Bookshelf ID: NBK536461
Contents

Views

Other titles in this collection

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...